Jim Simons
PTGX icon

Jim Simons’s Protagonist Therapeutics PTGX Stock Holding History

Jim Simons’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,167
Closed -$713K – 3598
2025
Q4 		$713K Buy
+8,167
New +$668K ﹤0.01% 2430
2025
Q3 		– Sell
-173,134
Closed -$9.57M – 3818
2025
Q2 		$9.57M Sell
173,134
-150,433
-46% -$7.22M 0.01% 1079
2025
Q1 		$15.6M Buy
323,567
+102,400
+46% +$4.29M 0.02% 771
2024
Q4 		$8.54M Buy
221,167
+77,000
+53% +$3.36M 0.01% 1114
2024
Q3 		$6.49M Sell
144,167
-153,300
-52% -$6.19M 0.01% 1283
2024
Q2 		$10.3M Buy
297,467
+264,900
+813% +$7.76M 0.02% 900
2024
Q1 		$942K Sell
32,567
-181,400
-85% -$4.94M ﹤0.01% 2526
2023
Q4 		$4.91M Sell
213,967
-12,301
-5% -$215K 0.01% 1358
2023
Q3 		$3.77M Sell
226,268
-163,999
-42% -$3.18M 0.01% 1465
2023
Q2 		$10.8M Sell
390,267
-300,600
-44% -$7.52M 0.02% 982
2023
Q1 		$15.9M Buy
690,867
+432,000
+167% +$7.26M 0.02% 845
2022
Q4 		$2.82M Sell
258,867
-140,900
-35% -$1.19M ﹤0.01% 1860
2022
Q3 		$3.37M Buy
399,767
+76,900
+24% +$728K ﹤0.01% 1690
2022
Q2 		$2.55M Buy
322,867
+303,400
+1,559% +$3.67M ﹤0.01% 2016
2022
Q1 		$461K Buy
+19,467
New +$548K ﹤0.01% 3248
2021
Q1 		– Sell
-35,797
Closed -$722K – 3622
2020
Q4 		$722K Sell
35,797
-300,903
-89% -$6.48M ﹤0.01% 2663
2020
Q3 		$6.58M Sell
336,700
-195,600
-37% -$3.67M 0.01% 1408
2020
Q2 		$9.4M Sell
532,300
-43,100
-7% -$541K 0.01% 1261
2020
Q1 		$4.06M Sell
575,400
-42,724
-7% -$320K ﹤0.01% 1689
2019
Q4 		$4.36M Buy
618,124
+63,024
+11% +$626K ﹤0.01% 1938
2019
Q3 		$6.67M Buy
555,100
+42,800
+8% +$539K 0.01% 1641
2019
Q2 		$6.2M Buy
512,300
+107,300
+26% +$1.19M 0.01% 1694
2019
Q1 		$5.09M Buy
405,000
+65,200
+19% +$575K ﹤0.01% 1800
2018
Q4 		$2.29M Sell
339,800
-197,400
-37% -$1.57M ﹤0.01% 2163
2018
Q3 		$5.53M Buy
537,200
+58,900
+12% +$507K 0.01% 1739
2018
Q2 		$3.21M Buy
478,300
+426,100
+816% +$3.27M ﹤0.01% 2034
2018
Q1 		$448K Buy
+52,200
New +$983K ﹤0.01% 2951
2017
Q3 		– Sell
-25,989
Closed -$294K – 3328
2017
Q2 		$294K Buy
+25,989
New +$278K ﹤0.01% 2909

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Jim Simons's PTGX Position: Q1 2026 in Review

Jim Simons sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 8,167 shares — an estimated $713K sold.

Jim Simons first reported a position in PTGX in Q2 2017 and held it in 28 quarters. The position peaked at $15.9M in Q1 2023. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Jim Simons reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 8,167 Protagonist Therapeutics shares in Q1 2026, an estimated $713K.
  • Jim Simons first reported a position in Protagonist Therapeutics in Q2 2017 and held it in 28 quarters.
  • Jim Simons's Protagonist Therapeutics position peaked at $15.9M in Q1 2023.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.